Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast

H. N. Raaf, D. W. Jacobsen, S. Savon, Ralph Green

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The transferrin receptor is expressed on the surface of rapidly dividing cells that require iron as a co-factor for essential redox reactions and deoxyribonucleotide synthesis. Transferrin receptors are expressed on the surface of breast carcinoma cells but not on benign breast tumor cells. In this study, the authors investigated whether transferrin receptor concentrations in the serum were elevated in patients with invasive adenocarcinoma of the breast. The transferrin receptor was isolated and purified from human placenta by affinity chromatography. The serum transferrin receptor concentration was determined using an enzyme-linked immunosorbent assay in 19 patients with invasive breast adenocarcinoma, 12 of whom had involvement of axillary lymph nodes. These results were compared with those from 16 normal age-matched female controls. In the invasive breast cancer group, the range of transferrin receptor concentrations was 2.60-7.34 mg/L (mean, 4.44 mg/L) compared with 2.85-8.80 mg/L (mean, 5.49 mg/L) in the control group. Nine patients with in situ adenocarcinoma of the breast had transferrin receptor concentrations of 3.68-6.66 mg/L (mean, 4.94 mg/L). For both the invasive carcinoma group and the in situ group, the means were not significantly different from those of the control group (P = 0.06 and 0.32, respectively). It was concluded that the differential expression of transferrin receptor on the surface of malignant tumor cells in adenocarcinoma of the breast was not reflected by changes in circulating transferrin receptor concentrations.

Original languageEnglish (US)
Pages (from-to)232-237
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume99
Issue number3
StatePublished - 1993
Externally publishedYes

Fingerprint

Transferrin Receptors
Adenocarcinoma
Breast
Serum
Breast Neoplasms
Deoxyribonucleotides
Control Groups
Carcinoma in Situ
Affinity Chromatography
Placenta
Oxidation-Reduction
Iron
Lymph Nodes
Enzyme-Linked Immunosorbent Assay

Keywords

  • Breast carcinoma
  • Enzyme-linked immunosorbent assay
  • Serum transferrin receptor
  • Transferrin receptor
  • Tumor markers

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast. / Raaf, H. N.; Jacobsen, D. W.; Savon, S.; Green, Ralph.

In: American Journal of Clinical Pathology, Vol. 99, No. 3, 1993, p. 232-237.

Research output: Contribution to journalArticle

@article{28e05f9a609c4e318ac9f360b3684a2c,
title = "Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast",
abstract = "The transferrin receptor is expressed on the surface of rapidly dividing cells that require iron as a co-factor for essential redox reactions and deoxyribonucleotide synthesis. Transferrin receptors are expressed on the surface of breast carcinoma cells but not on benign breast tumor cells. In this study, the authors investigated whether transferrin receptor concentrations in the serum were elevated in patients with invasive adenocarcinoma of the breast. The transferrin receptor was isolated and purified from human placenta by affinity chromatography. The serum transferrin receptor concentration was determined using an enzyme-linked immunosorbent assay in 19 patients with invasive breast adenocarcinoma, 12 of whom had involvement of axillary lymph nodes. These results were compared with those from 16 normal age-matched female controls. In the invasive breast cancer group, the range of transferrin receptor concentrations was 2.60-7.34 mg/L (mean, 4.44 mg/L) compared with 2.85-8.80 mg/L (mean, 5.49 mg/L) in the control group. Nine patients with in situ adenocarcinoma of the breast had transferrin receptor concentrations of 3.68-6.66 mg/L (mean, 4.94 mg/L). For both the invasive carcinoma group and the in situ group, the means were not significantly different from those of the control group (P = 0.06 and 0.32, respectively). It was concluded that the differential expression of transferrin receptor on the surface of malignant tumor cells in adenocarcinoma of the breast was not reflected by changes in circulating transferrin receptor concentrations.",
keywords = "Breast carcinoma, Enzyme-linked immunosorbent assay, Serum transferrin receptor, Transferrin receptor, Tumor markers",
author = "Raaf, {H. N.} and Jacobsen, {D. W.} and S. Savon and Ralph Green",
year = "1993",
language = "English (US)",
volume = "99",
pages = "232--237",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast

AU - Raaf, H. N.

AU - Jacobsen, D. W.

AU - Savon, S.

AU - Green, Ralph

PY - 1993

Y1 - 1993

N2 - The transferrin receptor is expressed on the surface of rapidly dividing cells that require iron as a co-factor for essential redox reactions and deoxyribonucleotide synthesis. Transferrin receptors are expressed on the surface of breast carcinoma cells but not on benign breast tumor cells. In this study, the authors investigated whether transferrin receptor concentrations in the serum were elevated in patients with invasive adenocarcinoma of the breast. The transferrin receptor was isolated and purified from human placenta by affinity chromatography. The serum transferrin receptor concentration was determined using an enzyme-linked immunosorbent assay in 19 patients with invasive breast adenocarcinoma, 12 of whom had involvement of axillary lymph nodes. These results were compared with those from 16 normal age-matched female controls. In the invasive breast cancer group, the range of transferrin receptor concentrations was 2.60-7.34 mg/L (mean, 4.44 mg/L) compared with 2.85-8.80 mg/L (mean, 5.49 mg/L) in the control group. Nine patients with in situ adenocarcinoma of the breast had transferrin receptor concentrations of 3.68-6.66 mg/L (mean, 4.94 mg/L). For both the invasive carcinoma group and the in situ group, the means were not significantly different from those of the control group (P = 0.06 and 0.32, respectively). It was concluded that the differential expression of transferrin receptor on the surface of malignant tumor cells in adenocarcinoma of the breast was not reflected by changes in circulating transferrin receptor concentrations.

AB - The transferrin receptor is expressed on the surface of rapidly dividing cells that require iron as a co-factor for essential redox reactions and deoxyribonucleotide synthesis. Transferrin receptors are expressed on the surface of breast carcinoma cells but not on benign breast tumor cells. In this study, the authors investigated whether transferrin receptor concentrations in the serum were elevated in patients with invasive adenocarcinoma of the breast. The transferrin receptor was isolated and purified from human placenta by affinity chromatography. The serum transferrin receptor concentration was determined using an enzyme-linked immunosorbent assay in 19 patients with invasive breast adenocarcinoma, 12 of whom had involvement of axillary lymph nodes. These results were compared with those from 16 normal age-matched female controls. In the invasive breast cancer group, the range of transferrin receptor concentrations was 2.60-7.34 mg/L (mean, 4.44 mg/L) compared with 2.85-8.80 mg/L (mean, 5.49 mg/L) in the control group. Nine patients with in situ adenocarcinoma of the breast had transferrin receptor concentrations of 3.68-6.66 mg/L (mean, 4.94 mg/L). For both the invasive carcinoma group and the in situ group, the means were not significantly different from those of the control group (P = 0.06 and 0.32, respectively). It was concluded that the differential expression of transferrin receptor on the surface of malignant tumor cells in adenocarcinoma of the breast was not reflected by changes in circulating transferrin receptor concentrations.

KW - Breast carcinoma

KW - Enzyme-linked immunosorbent assay

KW - Serum transferrin receptor

KW - Transferrin receptor

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0027417773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027417773&partnerID=8YFLogxK

M3 - Article

C2 - 8447283

AN - SCOPUS:0027417773

VL - 99

SP - 232

EP - 237

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -